Actinic Keratosis Treatment Market Size, Share & Trends Analysis Report By Therapy (Topical, Surgery, Photodynamic Therapy), By Drug Class, By End Use, By Region, And Segment Forecasts, 2019 - 2026

Industry Insights

The global actinic keratosis treatment market size was valued at USD 6.3 billion in 2018 and is estimated to expand at a CAGR of 4.8% over the forecast period. Increase in disease prevalence, aided by environmental factors, such as ozone depletion and excessive sun exposure, is one of the key drivers for market growth.

Actinic keratosis is the most prevalent class of precancerous skin lesions. Nearly 50% of all squamous cell carcinoma cases arise from untreated or inappropriately treated actinic keratoses. Preventive strategies for cancer are the major propeller for increased treatment rates of actinic keratosis.

Several awareness campaigns organized by public and private groups are anticipated to catalyze consumer awareness about the disease and its comorbidities. In addition, favorable reimbursement policies to expand the affordability will drive market growth.

The impending launch of pipeline products, combined with the research and development of novel treatments with improved efficacy, convenient dosage, and reduced cost, indicates a promising future for the actinic keratosis treatment market.

Therapy Insights

Topical products led the actinic keratosis therapies in 2018, driven by easy availability and deep market penetration. Topical treatments are used for targeting a wide area of visible and invisible lesions on the skin. Also called field therapy, topical treatments have a low risk of scarring.

Surgical procedures for actinic keratosis treatment is likely to lose market shares over the next few years due to alternative therapies that do not physically destruct skin tissues or cause permanent scars. Photodynamic therapy is swiftly gaining ground, marked by their increasing market absorption and significant commercial opportunities.

End Use Insights

Hospitals end use segment led the market, in 2018. The growth is driven by ease of accessibility and availability to patients. The rise in healthcare infrastructure, especially in developing economies, is a key driver.

Homecare is anticipated to demonstrate a rapid growth over the forecast period, supported by high consumer awareness and self-care treatment options. Furthermore, increasing opportunities for caregivers and nurses for home healthcare services are a major propeller for actinic keratosis treatment market growth.

Drug Class Insights

Nucleoside metabolic inhibitors held the largest market share in 2018, and is anticipated to continue through the forecast period. The market growth is driven by steady sales of Carac, Efudex, Fluoroplex, and Tolak. However, generic penetration is likely to have a negative impact on the market.

Photoenhancers are projected to witness a healthy growth over the next few years by virtue of strong commercial opportunities and relatively low competitive rivalry. NSAIDs and immune response modifiers are forecasted to maintain their market shares in the foreseeable future.

Regional Insights

North America led the market in 2018, by contributing nearly 35.0% to the overall revenue share, driven by an increasing disease prevalence and proactive government initiatives. Local presence of key manufacturers as well as regulatory entities is anticipated to foster market growth in the near future.

Asia Pacific is estimated to expand at a lucrative CAGR over the forecast period. The high prevalence of the disease in southern areas, such as Australia and New Zealand, is the major regional growth driver. In addition, increasing disposable income and rise in consumer awareness contribute significantly to the rapid regional growth.

Actinic Keratosis Treatment Market Share Insights

Some key players in the market include Bausch Health Companies Inc.; LEO Pharma A/S; Almirall, S.A.; Biofrontera, Inc.; Nestlé S.A.; Sun Pharmaceutical Industries Ltd.; Novartis International AG; 3M Pharmaceuticals Inc.; Hill Dermaceuticals, Inc.; and Mylan N.V.

Innovative research and development, such as photodynamic therapy, plays a key role in entrance of new players in this market. In addition, key players are adopting various strategies such as mergers and acquisitions, new product developments, and promoting awareness initiatives to maintain their market share.

Report Scope

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2014 to 2026. For the purpose of this study, Grand View Research has segmented the global actinic keratosis treatment market report on the basis of therapy, drug class, end use, and region:

• Therapy Outlook (Revenue, USD Million; 2014 - 2026)

  • Topical

  • Surgery

  • Photodynamic Therapy

• Drug Class Outlook (Revenue, USD Million; 2014 - 2026)

  • Nucleoside Metabolic Inhibitors

  • NSAIDs

  • Immune Response Modifiers

  • Photoenhancers

  • Others

• End use Outlook (Revenue, USD Million; 2014 - 2026)

  • Hospitals

  • Private Clinics

  • Homecare

  • Others

• Regional Outlook (Revenue, USD Million; 2014 - 2026)

  • North America 

    • U.S.

    • Canada

  • Europe 

    • U.K.

    • Germany

    • Spain

    • France

    • Italy

  • Asia Pacific 

    • Japan

    • China

    • India

    • South Korea

    • Australia

  • Latin America 

    • Brazil

    • Mexico

    • Argentina

  • Middle East & Africa 

    • South Africa

    • Saudi Arabia

    • UAE